Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience)
Aim of the study. To estimate efficacy and safety of cepeginterferon-alpha 2b (cPEG-IFNα2b) and ribavirin combination for the treatment of chronic hepatitis C (CHC), to define necessity of IL-28V genetic polymorphism diagnostics, to estimate liver elastometry scores at the background of antiviral th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2018-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860292009852928 |
|---|---|
| author | I. Yu. Pirogova N. B. Kovaleva E. P. Patlusov E. S. Radchenko |
| author_facet | I. Yu. Pirogova N. B. Kovaleva E. P. Patlusov E. S. Radchenko |
| author_sort | I. Yu. Pirogova |
| collection | DOAJ |
| description | Aim of the study. To estimate efficacy and safety of cepeginterferon-alpha 2b (cPEG-IFNα2b) and ribavirin combination for the treatment of chronic hepatitis C (CHC), to define necessity of IL-28V genetic polymorphism diagnostics, to estimate liver elastometry scores at the background of antiviral therapy. Material and methods. Overall 164 patients with hepatitis C viruses (HCV) genotypes 1, 2 and 3 in 4 medical centers received antiviral therapy. All patients received cPEG-IFNα2band ribavirin. The treatment mode and dose of drugs conformed to the existing standards. Treatment response was defined by the frequency of sustained virologic response (SVR) achievement. All patients were included in the treatment safety analysis. Besides that, in 104 patients liver tissue elasticity scores dynamics was estimated according to elastometry data. Results. Results of double mode antiviral therapy (cPEG-IFNα2band ribavirin) at treatment of 164 CHC patients were analyzed: 58.5% (n=96) - patients had HCV genotypes 2-3, 41.5% (n=68) of patients - HCV genotype 1. The majority of the patients had mild fibrosis and low viral load. Overall SVR was achieved in 86.5% of patients (n=142). Of patients with HCV genotype 1 the rate of SVR was 79.4% (n=54), in patients with genotypes 2 and 3 - 91.7% (n=88). In patients with the IL-28V genotype variant C/C the SVR rate was 93.7% (n=45): in 100% of patients with HCV genotypes 2 and 3 and in 85.7% of patients with HCV genotype 1. In 83,7% of the patients included in the analysis no statistically significant dynamics of liver tissue density was noted. Conclusion. As administration of interferon-free treatment modes for most of patients is limited due to financial considerations, application of IFN-based modes of treatment in clinical practice is still actual. Results of the present study demonstrate that screening for treatment candidates allows to achieve high efficacy and favorable safety profile of double treatment mode (cPEG-IFNα2b and ribavirin). |
| format | Article |
| id | doaj-art-7ea32df125df4efc9eebb813ba138295 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2018-08-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-7ea32df125df4efc9eebb813ba1382952025-02-10T16:14:29ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-08-01281414910.22416/1382-4376-2018-28-1-41-49216Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience)I. Yu. Pirogova0N. B. Kovaleva1E. P. Patlusov2E. S. Radchenko3LLC «Medical center “Lotos”»State educational government-financed institution of higher professional education «Ural state medical university»Military clinical hospital #5Khanty-Mansi Yugra autonomous government-financed regional institution «Surgut regional clinical hospital»Aim of the study. To estimate efficacy and safety of cepeginterferon-alpha 2b (cPEG-IFNα2b) and ribavirin combination for the treatment of chronic hepatitis C (CHC), to define necessity of IL-28V genetic polymorphism diagnostics, to estimate liver elastometry scores at the background of antiviral therapy. Material and methods. Overall 164 patients with hepatitis C viruses (HCV) genotypes 1, 2 and 3 in 4 medical centers received antiviral therapy. All patients received cPEG-IFNα2band ribavirin. The treatment mode and dose of drugs conformed to the existing standards. Treatment response was defined by the frequency of sustained virologic response (SVR) achievement. All patients were included in the treatment safety analysis. Besides that, in 104 patients liver tissue elasticity scores dynamics was estimated according to elastometry data. Results. Results of double mode antiviral therapy (cPEG-IFNα2band ribavirin) at treatment of 164 CHC patients were analyzed: 58.5% (n=96) - patients had HCV genotypes 2-3, 41.5% (n=68) of patients - HCV genotype 1. The majority of the patients had mild fibrosis and low viral load. Overall SVR was achieved in 86.5% of patients (n=142). Of patients with HCV genotype 1 the rate of SVR was 79.4% (n=54), in patients with genotypes 2 and 3 - 91.7% (n=88). In patients with the IL-28V genotype variant C/C the SVR rate was 93.7% (n=45): in 100% of patients with HCV genotypes 2 and 3 and in 85.7% of patients with HCV genotype 1. In 83,7% of the patients included in the analysis no statistically significant dynamics of liver tissue density was noted. Conclusion. As administration of interferon-free treatment modes for most of patients is limited due to financial considerations, application of IFN-based modes of treatment in clinical practice is still actual. Results of the present study demonstrate that screening for treatment candidates allows to achieve high efficacy and favorable safety profile of double treatment mode (cPEG-IFNα2b and ribavirin).https://www.gastro-j.ru/jour/article/view/216хронический гепатит спротивовирусная терапияцепэгинтерферон альфа 2bполиморфизм гена ил-28в |
| spellingShingle | I. Yu. Pirogova N. B. Kovaleva E. P. Patlusov E. S. Radchenko Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) Российский журнал гастроэнтерологии, гепатологии, колопроктологии хронический гепатит с противовирусная терапия цепэгинтерферон альфа 2b полиморфизм гена ил-28в |
| title | Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) |
| title_full | Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) |
| title_fullStr | Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) |
| title_full_unstemmed | Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) |
| title_short | Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) |
| title_sort | differentiated approach at the choice of chronic hepatitis c antiviral therapy mode real clinical practice experience |
| topic | хронический гепатит с противовирусная терапия цепэгинтерферон альфа 2b полиморфизм гена ил-28в |
| url | https://www.gastro-j.ru/jour/article/view/216 |
| work_keys_str_mv | AT iyupirogova differentiatedapproachatthechoiceofchronichepatitiscantiviraltherapymoderealclinicalpracticeexperience AT nbkovaleva differentiatedapproachatthechoiceofchronichepatitiscantiviraltherapymoderealclinicalpracticeexperience AT eppatlusov differentiatedapproachatthechoiceofchronichepatitiscantiviraltherapymoderealclinicalpracticeexperience AT esradchenko differentiatedapproachatthechoiceofchronichepatitiscantiviraltherapymoderealclinicalpracticeexperience |